To test in vivo anti-tumor activity of TGI1002 and further confirm that TGI1002 directly act on the interaction of SET-PP2A, a xenografted mouse model bearing BaF3-p210T315I was established by implanting tumor cells, and TGI1002 was intraperitoneally administrated to determine anti-tumor efficacy using ponatinib as a positive control. The gene discussed is PTPA; the disease is neoplasm.